Daily reporting, analysis, and legal-market coverage across patents, trademarks, copyright, licensing, disputes, and policy.
1 article published on this day, newest first.
The underlying dispute centers on Novartis' U.S. Patent No. 8,101,659, which covers the use of sacubitril/valsartan (sold under the brand name Entresto) for treating heart failure with reduced ejection fraction (HFrEF...
Get Top 5 IP News Today, weekly editorial roundups, and region-aware updates tailored to your practice.
The underlying dispute centers on Novartis' U.S. Patent No. 8,101,659, which covers the use of sacubitril/valsartan (sold under the brand name Entresto) for treating heart failure with reduced ejection fraction (HFrEF...
Practical patents context for IP teams tracking Patents, Envoy Medical Announces New, Patents Expanding Intellectual Property.
IIPLA reviews the patents implications of Patents, Envoy Medical Announces New, Patents Expanding Intellectual Property, with practical notes for global IP teams monitoring risk, enforcement, licensing, and portfolio strategy.
Practical trademarks context for IP teams tracking Trademarks, Tether, Korean.
IIPLA reviews the trademarks implications of Trademarks, Tether, Korean, with practical notes for global IP teams monitoring risk, enforcement, licensing, and portfolio strategy.